Ondo Finance, a company offering blockchain-based products tied to U.S. Treasurys and stocks valued over $3.8 billion, is looking for potential buyers following the death of its founder and CEO, Nathan Allman. The sale process may be delayed due to a legal dispute over company control. Ondo's products provide investors exposure to U.S. government debt and equities through tokenization, a growing trend in finance. The outcome of the sale and legal issues will impact the future of these tokenized financial products.
Ondo Finance's sale prospects following its founder's death provide context for readers interested in blockchain finance. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Sep 25, 2026 03:01 WIB: out of 50 major cryptocurrencies, 44 rose and 5 fell. Notably, CAKE rose 7.23% to Rp49.273 with a typical hold time of 75 days and a Pluang order activity skewed 72% Sell / 28% Buy, contrasting with DOT which rose 7.17% to Rp20.944 with a longer hold time of 120 days and a strong 91% Buy activity. SAND increased 6.86% to Rp768 with a hold time of 123 days and 62% Buy activity, showing varied investor behavior across these assets.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
